European Society of Anaesthesiology and Intensive Care (ESAIC) Recommends Noninvasive, Continuous Hemoglobin Monitoring

Masimo has announced that updated guidelines published by the European Society of Anesthesiology and Intensive Care (ESAIC) highlight the value of continuous, non-invasive hemoglobin (Hb) monitoring to help patients Clinician controlling perioperative bleeding. Referencing studies using technologies such as Masimo SpHb®, the guideline notes that “the use of non-invasive Hb monitoring methods can be a practical approach for continuous monitoring of Hb levels and cause no further blood loss.”Noting that in this area of care, it is “essential to remain informed by the latest evidence,” the ESAIC, which has pledged to revisit its perioperative blood management guidelines at least every five years, has just published its updated findings, the result of a systematic review of research published from 2015 to 2021. Noting that managing bleeding during surgery is complex and “involves multiple assessment tools and strategies to ensure optimal patient care,” the guidelines cover numerous modalities, disciplines, scenarios, and patient populations – including how noninvasive, continuous hemoglobin monitoring offers a valuable way to improve blood management.In the updated guidelines, the ESAIC notes a major drawback to measuring hemoglobin during surgery using blood gas analyzers and invasive blood sampling: “single measurements taken at different time points may not depict accurate values.” In addition, they note, excess blood sampling can lead to iatrogenic blood loss and hospital-acquired anemia. While noninvasive hemoglobin monitoring is not intended to replace invasive blood sampling, it may offer a “practical approach to monitor[ing] the Hb concentration continuously and without accumulating additional blood losses.”The guidelines also note its value “for trend analysis and to monitor changes in addition to laboratory-measured Hb concentrations during the intervals between invasive blood sampling and Hb measurements.” The guidelines continue, “Having access to continuous measurements of Hb concentrations offers timely detection of changes in Hb concentrations and adjustment, if necessary, in the clinical setting.”In their summary of the guidance derived from their systematic literature review, the guidelines also note that when severe bleeding and volume shifts are expected or occurring, “continuous noninvasive hemoglobin monitoring may be considered for trend analyses and for reducing blood sampling for invasive laboratory measurement of hemoglobin concentration, especially in children.”Launched in 2008, Masimo SpHb is part of the rainbow® Pulse CO-Oximetry platform, available on a variety of Masimo Pulse CO-Oximeters® and on devices from numerous third-party manufacturers, including Draeger, GE, Philips, and ZOLL. Utilizing multiple wavelengths of light, SpHb provides real-time, continuous visibility to changes in the hemoglobin trend between invasive blood samples.In inpatient blood management programs, SpHb has been shown to improve outcomes for both high and low-blood loss surgeries, such as reducing the proportion of patients receiving allogeneic blood transfusions, by 2.3 erythrocyte transfusion per patient, 4-6 transfusion time reduction,7 cost reduction,8 and even 30- and 90-day mortality reductions after surgery by 33% and 29%, respectively (when combined with a targeted fluid therapy algorithm using Masimo PVi®). 9 Evidence of SpHb impact on outcomes spans the globe, now representing 7 countries on 4 different continents.2-10 Today, Masimo SpHb technology helps clinicians and care for patients in more than 75 countries.

“Noninvasive hemoglobin measurements now represent the standard of care in many clinical scenarios. With their inclusion in the latest perioperative bleeding guidelines, we hope that more anesthesiologists around the world incorporate this technology into their daily practice to help improve overall patient blood management.”

Professor Kai Zacharowski, past President of ESAIC and senior author of the guidelines.

“The ESAIC holds the most prominent position in the community of anaesthesiologists and intensivists in Europe and elsewhere. We are pleased to share the updated guidelines with the goal of improving patient outcomes by focusing on the quality of care and patient safety strategies. Noninvasive hemoglobin monitoring has an important role throughout the perioperative period and in acute care, as it can provide trend data for more informed decision-making. We look forward to seeing it adopted more widely for better patient care.”

Professor Edoardo De Robertis, current President of ESAIC and co-author of the guidelines.

“With laboratory measurements, and even with bedside point-of-care hemoglobin testing, results are intermittent, sampling errors can occur, and performing these tests can be distracting during complex cases and while caring for critically ill patients. SpHb monitoring provides real-time visibility to hemoglobin levels throughout the continuum of care and has the advantages of trend analysis as well as reductions in workload and delay, enabling clinicians to adjust blood management and observe results simultaneously.”

Dr. William C. Wilson, Chief Medical Officer, Masimo.

“Since its introduction 15 years ago, we’ve been heartened to see more and more clinicians around the world adopt SpHb as their standard of care, more and more clinical studies demonstrate its utility and more and more esteemed organizations like ESAIC recognize the benefits of noninvasive hemoglobin monitoring. The result of years of development and continued refinement, powered by our expertise in advanced signal processing techniques, SpHb plays a critical role in our mission to improve patient outcomes, reduce the cost of care, and ultimately, improve life.”

Joe Kiani, Founder and CEO of Masimo.

SpHb is not intended to replace laboratory blood tests. Clinical decisions regarding red blood cell transfusion should be based on the clinician’s judgment taking into account other factors, the patient’s condition, ongoing SpHb monitoring, and diagnostic laboratory tests. using blood samples.
Next Post

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care, Inc., a leader in insulin delivery and diabetes technology, today announced that it has published the results of the Pediatric Artificial Pancreas (PEDAP) clinical trial in the New England Journal of Medicine. Tag range for children aged 2-5 with t*:With advanced Control IQ hybrid closed-loop technology**, the […]